| Document |
Document Title |
|
WO/2006/133339A2 |
Monoamine re-uptake inhibitors and more specifically serotonin and noradrenaline re-uptake inhibitors are disclosed that have utility in the treatment of disorders of the central or peripheral nervous system in both men and women. The co...
|
|
WO/2006/125675A1 |
The invention relates to a method for isolating a stereoisomer from a mixture comprising two stereoisomers of general formulas (I-A) and (I-A') and/or two stereoisomers of general formulas (I-B) and (I-B'), wherein R1, R2, and R3 are ide...
|
|
WO/2006/122788A1 |
The present invention provides a compound of formula (I) wherein: R1 is a group selected from -CH2OH, -NHC(O)H and R2 is a hydrogen atom; or R1 together with R2 form the group -NH-C(O)-CH=CH- wherein the nitrogen atom is bound to the car...
|
|
WO/2006/123517A1 |
There is provided a novel crystal polymorph of ethyl (-)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methyle
thyl]amino]ethyl]-2,5-dimethylphenoxyacetate hydrochloride which can be identified by characteristic diffraction peaks of p...
|
|
WO/2006/123672A1 |
Disclosed is a method for commercially producing an aminoalcohol derivative (I) having a biphenyl group. Also disclosed are a biphenyloxyacetaldehyde derivative used therefor, a method for producing such a biphenyloxyacetaldehyde derivat...
|
|
WO/2006/118087A1 |
There is provided ethyl (-)-2-[4-[2-[[1S,2R]-2-hydroxy-2-(4-hydroxyphenyl)-1-methyle
thyl]amino]ethyl]-2,5-dimethylphenoxyacetate hydrochloride 1/4 hydrate or its crystal, which can be identified by characteristic diffraction peaks of po...
|
|
WO/2006/114264A1 |
The invention provides compounds of formula (I), wherein the substituents are as defined in the specification, to processes for their preparation and their use as pharmaceuticals.
|
|
WO/2006/115154A1 |
There are provided &agr -, β- and &gammad -crystals produced by treating with a specified solvent 4’-&lcub 2-[(1S,2R)-2-hydroxy-2-(4-hydroxyphenyl)-1-methylethylamino]
ethoxy&rcub -3-isopropyl-3’,5’-dimethylbiphenylcarboxylic acid...
|
|
WO/2006/114323A2 |
The present invention concerns novel orthogonally protected amino acids, there production and use for the synthesis of binding Compounds usable in the diagnosis and treatment of proliferative diseases, in particular tumor diseases.
|
|
WO/2006/108712A1 |
The invention relates to poly-substituted tetrahydronaphtalene derivatives of formula (I) and to a method for the production and the use thereof in the form of antiphlogistics.
|
|
WO/2006/108120A1 |
Stable Atomoxetine hydrochloride, a process for the manufacture thereof, the use of stable Atomoxetine Hydrochloride for making a pharmaceutical formulation, a process for the preparation of any form of Atomoxetine Hydrochloride, and an ...
|
|
WO/2006/093014A1 |
This invention provides a compound represented by general formula (1): (1) wherein R1, R2, R3, R4, and R5 each independently represent one group selected from a hydrogen atom and methyl, acetyl, hydroxyl, and alkoxy groups; and X represe...
|
|
WO/2006/089708A1 |
This invention relates to solid crystalline forms of (1 RS,3RS,6RS)-6- Dimethylaminomethyl-1-(3-methoxy-phenyl)cyclohexane-1 ,3-diol hydrochloride (1), methods of producing 1, methods of use of 1, use of 1 as analgesics and pharmaceutica...
|
|
WO/2006/089707A1 |
The invention relates to 6-dimethylaminomethyl-l-(3- methoxyphenyl) -1,3-dihydroxycyclohexane compounds in the form of phosphate salts, to processes for preparing them and to the use of these compounds in pharmaceuticals.
|
|
WO/2006/088525A1 |
Methods for the preparation of stereoisomerically substantially aminocyclohexyl ether compounds such as trans-(1R,2R)-aminocyclohexyl ether compounds and/or trans-(1S,2S)-aminocyclohexyl ether compounds as well as various intermediates a...
|
|
WO/2006/085493A1 |
An aromatic diamine represented by the following formula (I): (wherein R1 to R6 each independently represent hydrogen, an alkyl group or an aryl group and may be the same or different). The aromatic diamine is useful as a curing agent fo...
|
|
WO2004064762A9 |
The present disclosure relates to novel cocrystals and novel methods for cocrystallization. In particular, the disclosure includes cocrystals comprising a salt of an active agent, such as a chloride salt of an active pharmaceutical ingre...
|
|
WO/2006/072785A2 |
The present invention relates to novel base stable ionic liquids and uses thereof as solvents in chemical reactions, especially base catalysed chemical reactions and reactions comprising the use of strong basis.
|
|
WO/2006/072775A2 |
Use of ionic liquids as solvents in base-catalysed chemical reactions wherein the ionic liquid is composed of at least one species of cation and at least one species of anion, characterised in that a cation of the ionic liquid comprises ...
|
|
WO/2006/068662A1 |
Provided are processes for preparing tomoxetine comprising reacting Nmethyl-3-hydroxy-3-phenylpropylamine with dimethylsulfoxide (DMSO) and 2-fluorotoluene in the presence of an alkali base to form tomoxetine. Also provided is the co...
|
|
WO/2006/066748A1 |
Compounds of the formula (I) or pharmaceutically acceptable salts thereof, wherein m, p, q, Ar, R1 and R 2 are as defined herein. Also provided are methods for preparing, compositions comprising, and methods for using compounds of formul...
|
|
WO/2006/063829A2 |
Compounds of methamphetamine derivatives having a meta-substituted alkyl linker on the benzene ring and a protective group on the nitrogen of the methamphetamine hapten. Such compounds have the structure (I) wherein R1 is an alkyl linker...
|
|
WO/2006/056098A1 |
The invention relates to the process for resolving DL-ephedrine, DL-pseudoephedrine or the derivatives thereof and to the corresponding resolving agents. The D-(+)- or L-(-)-tartaric acid derivatives of formula (I) are the resolving agen...
|
|
WO/2006/050768A1 |
The invention relates to agents for colouring keratin fibres, in particular human hair, said agents containing at least one m-phenylenediamine derivative of formula (I) in a cosmetically acceptable medium as the coupler component. In sai...
|
|
WO/2006/050633A1 |
The invention relates to the process for resolving DL-ephedrine or the derivatives thereof and to the corresponding resolving agents. The L-(-)-dibenzoyl-tartaric acid or its derivatives of formula (I) are the resolving agents for DL-eph...
|
|
WO/2006/049182A1 |
Disclosed is a novel hydroxyalkylated polyalkylenepolyamine composition. Also disclosed is a method for producing such a hydroxyalkylated polyalkylenepolyamine composition at low cost. Further disclosed is a method for producing a polyur...
|
|
WO/2006/049014A1 |
An industrially practicable process for producing an &agr ,&agr -difluoroamine, which comprises using specific amounts of hydrogen fluoride and a Lewis base in a halogen-fluorine exchange reaction in which an &agr ,&agr -dihaloamine is u...
|
|
WO/2006/049860A1 |
An organic electroluminescent device comprises a cathode, an anode, and has therebetween a light-emitting layer comprising an emissive component represented by Formula (I) wherein: Ar1, each2, and Ar3 through Ar7 are independently select...
|
|
WO/2006/046593A1 |
Disclosed is an excellent LXR modulator. Specifically disclosed is a compound represented by the general formula (I) below or the like. (I) [In the formula, R1 represents a -COR9 (wherein R9 represents an alkyl, optionally substituted al...
|
|
WO/2006/045519A1 |
The present invention relates to an improved process for the preparation of substituted 2-(4-carbonylmethoxy-optionally 2,5-disubstituted-phenyl)-acetaldehydes, in particular 2-(4-alkoxycarbonylmethoxy- optionally 2,5-disubstituted-pheny...
|
|
WO/2006/043577A1 |
Disclosed is a novel method for producing a phenylethanolamine compound represented by the following general formula (III) (wherein R1 represents a hydrogen atom or a halogen atom, and R2 represents an alkyl group which may be substitute...
|
|
WO/2006/041015A1 |
Disclosed is an amino alcohol derivative having an excellent immunosuppressive effect and few side effects. Specifically disclosed is an amino alcohol derivative represented by the following general formula (1): (1) (whose specific examp...
|
|
WO/2006/041115A1 |
Disclosed is a fluorine-containing polymerizable monomer represented by the formula [1] below. (In the formula, A represents a single bond, an oxygen atom, a sulfur atom, CO, CH2, SO, SO2, C(CH3)2, NHCO, C(CF3)2, a phenyl or an alicyclic...
|
|
WO/2006/035685A1 |
Disclosed are novel production intermediates (IIa) and (III) of a 6-substituted-1-methyl-1-H-benzimidazole derivative (I) as a publicly-known pharmaceutically active ingredient. Also disclosed is a production method suitable for mass syn...
|
|
WO/2006/035457A1 |
The present invention provides an improved process for the preparation of Venlafaxine and the intermediates thereof. The present invention provides a process for preparing compound of formula (IV), an intermediate for preparing Venlafaxi...
|
|
WO/2006/034459A1 |
The present invention generally relates to a process for preparing the alkoxylated alkylamines and/or alkyl ether amines. The process consists of three stages, and utilizes an alkali catalyst. The alkoxylated alkyl amines and alkoxylated...
|
|
WO/2006/033318A1 |
A compound useful as an NMDA antagonist having a wide safety region which is a therapeutic agent for Alzheimer's disease, vascular dementia (vascular agnosia), Parkinson's disease, ischemic apoplexy, and pains or a preventive agent for t...
|
|
WO/2006/034093A2 |
The present invention provides BACE inhibitors of Formula (I); methods for their use and preparation, and intermediates useful for their preparation.
|
|
WO/2006/032893A2 |
The present invention provides a compound of the formula: (IIa); having a reactive functional group M, capable of reacting with a biopolymer, BP, having at least one group capable of reacting with M to form a covalent linkage, to provide...
|
|
WO/2006/029303A2 |
This invention relates to diphenyl ether derivatives and their use in imaging of Serotonin Transporters (SERTS). The present invention also provides diagnostic compositions comprising the compounds of the present invention, and a pharmac...
|
|
WO/2006/027039A1 |
The invention relates to P-diaminobenzole-derivatives of general formula (I) or to the physiologically compatible, water-soluble salts thereof, in addition to dyes containing said compounds for keratin fibres.
|
|
WO/2006/027684A1 |
This invention is directed to compounds of formula la, lb or Ic and to pharmaceutical compositions thereof: formula (Ia), formula (Ib), formula (Ic) or a prodrug thereof and a pharmaceutically acceptable carrier, wherein the R groups are...
|
|
WO/2006/021564A1 |
This invention relates to novel substituted aryloxy alkylamines useful as monoamine neurotransmitter re-uptake inhibitors. In other aspects the invention relates to the use of these compounds in a method for therapy and to pharmaceutical...
|
|
WO/2006/022237A1 |
Disclosed is a medicament for preventing or treating fatty liver. Specifically disclosed is a pharmaceutical composition characterized by containing a compound represented by the general formula (I): (wherein R1 and R2 respectively repre...
|
|
WO/2006/023883A2 |
The present invention provides novel T type calcium channel inhibitors of formula (I), the use thereof in the treatment of a disease or condition in a mammal associated with influx of extracellular calcium via T type calcium channels, wh...
|
|
WO/2006/020348A2 |
The present invention provides novel crystalline polymorph forms of atomoxetine hydrochloride denominated Forms B and C and methods for their preparation, as well as methods for the preparation of Form A. The present invention provides p...
|
|
WO/2006/014942A1 |
The invention encompasses compounds of Formula (I), including pharmaceutically acceptable salts and solvates, their pharmaceutical compositions, and their use in treating disorders associated with an excess or imbalance of tachykinins or...
|
|
WO/2006/015279A1 |
Heterocyclic diamine compounds of formula (I) are provided. Such compounds may be used to modulate MCH receptor activity in vivo or in vitro, and are particularly useful in the treatment of a variety of metabolic, feeding and sexual diso...
|
|
WO/2006/011469A1 |
A cyclohexane derivative having the function of reducing a blood sugar level and having preferable properties required of medicines, such as long-lasting drug activity, metabolic stability, and safety; and a medicinal composition for use...
|
|
WO/2006/004979A2 |
The present invention provides isolated N-methyl-3-(3-methylphenoxy)-3-phenylpropylamine hydrochloride, and preparation thereof as well as of N-methyl-3-(4-methylphenoxy)-3-phenylpropylamine hydrochloride and of N-methyl-3-phenoxy-3-phen...
|
